Biotechnology

KLK1 Expands Possibilities to Restore Vascular Health

By restoring the body’s ability to produce KLK1, therapies are emerging for pree...

AI Tackles Tuberculosis, Identifies Drugs that Penetrat...

Researchers have developed a new AI approach to select chemical compounds that c...

Bioprocessing at Full Throttle

Intensified strategies are reshaping biologics manufacturing by boosting speed, ...

Biomanufacturing in Space to Be Key Topic at ISSCR 2026

Scientists from the Cedars-Sinai Board of Governors Regenerative Medicine Instit...

Unlocking Microbiome Function with Anaerobic Workflows ...

This eBook explores how researchers can move beyond correlation and towards mech...

New sa‑mRNA and LNP Platform to Support Korea’s Hantavi...

Building on promising preclinical findings, researchers in South Korea are devel...

Pharma Races to Scale AI as Billions Flow into Drug Dis...

Investors unpack what it takes to succeed in an increasingly crowded AI biology ...

Chimeric Allergen Receptor Treg Cells Suppress Allergic...

Researchers developed regulatory T cells armed with chimeric allergen receptors—...

ALS Drug Extends Survival in Mice, Targets TDP-43 Low-C...

A new therapeutic target shields nerve cells from the damage of ALS. A novel dru...

StockWatch: New UC Data Sparks Smoother Sailing for Abivax

Less than a month after its stock roller-coastered on safety signals associated ...

 A device that revives eyeballs from dead donors could ...

It’s not easy to transplant a whole human eye. The surgery is difficult. And the...

The UK’s generational tobacco ban might not work. I’m s...

As the parent of two little girls, I often think about how their childhood is di...

Synthetic Organizers Aid Creation of Reproducible Kidne...

Using techniques including spatial transcriptomics, researchers identified a dev...

ASMS 2026: Solving Proteomics’ Next Bottleneck

At the 74th ASMS Conference, the obvious story was hardware. But after several d...

Merck and Insilico Make Deals, Claude Science’s Debut, ...

In this episode of GEN's Touching Base, editors talk about the multi-billion-dol...

Elixirgen Builds Rare Disease Pipeline Around Telomere ...

Elixirgen's lead program is an ex vivo autologous therapy based on proprietary t...